glp 1 coverage Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss Reported work‐related impacts following GLP‐1

Misuse or unauthorized distribution is prohibited and may result in legal consequences

Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than 2.2 billion a year in hospital stays alone, said Dr Alison Cave, MHRAs Chief Safety Officer

Several dual GLP-1/GIP receptor agonists have been tested in phase 1 to phase 3 trials, including NNC0090-2746 (also known as RG7697), a fatty acylated version of a GLP-1/GIP co-agonist [16] and tirzepatide (also known as LY3298176) [17]

Only your doctor can determine which is right for you